"Our permitted status positions us favorably to capitalize on these market conditions, with the lower cost CK project production being attractive, particularly as established gold producers struggle to maintain production levels."
"We balance the need for speed in drug development with strict regulatory requirements by focusing on robust data, sound justifications and a well-structured technical package."
"Small molecule drugs dominate pharmaceutical development, holding almost 60% of the market in 2024, and FDA approvals for small molecules are expected to stay strong."
"Our focus is on advancing innovations in mine automation, efficient ventilation, mine design, and cooling systems to boost productivity and prioritize worker safety."
"For biotechs, finding the balance between appealing to the public and institutional investors will be a challenge, much like trying to balance a recipe with the right mix of ingredients for the perfect dish."
"New Jersey is home to eight of the top 10 global biopharmaceutical companies, nine of the top 10 R&D firms, and over 5,600 life sciences establishments. The State accounted for 43% of all novel FDA approvals in the past two years."
"Procos is poised for transformative growth in 2025. Our R11 facility will significantly enhance our small-scale production capacity, enabling us to meet the growing demand for high-quality, specialized APIs in the US market."
Québec and Atlantic Canada have traversed 2025 in an enviable position. Strong gold prices have buoyed balance sheets and investor sentiment, while global demand for critical minerals keeps the region firmly on the radar of international markets. At the same time, the provinces’ depth of mining expertise – from AI-driven exploration to advanced drilling, blasting, and geophysics – ensures that technological advantage is firmly on their side.